USPTO serial 99218536
BFB
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with BFB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Keith Toms, Esq.
Keith Toms, Esq. McCarter & English, LLP265 Franklin StreetBoston, MA 02110United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antibodies for medical purposes; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders | ACTIVE | — |
| 042 | Pharmaceutical research and development; Research and development services in the field of antibodies; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of proteomics, transcriptomics, and bioinformatics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 21, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 21, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 20, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 20, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 20, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 24, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 24, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 10, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 4, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 4, 2025 | NWAP | NEW APPLICATION ENTERED | — |